Exclusive Summary

• - Fully off-patent with generics widely launched since 2011–2013, enabling rapid distribution without IP barriers.
• - Targets allergic rhinitis and chronic urticaria with a global patient pool of ~400–600 million and 40–80 million, ensuring stable year-round demand.
• - Second-generation H1 antihistamine endorsed by ARIA/EAACI as first-line, once-daily and low-sedating, delivering solid clinical value.
• - EU27 registration with CTD dossier, BE data, PV and serialization compliance supports fast multi-country access and tender participation.
• - Typically 50–80% cheaper than originator, offering strong cost advantage for payers and retail channels.